Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 01-05-2022 | Streptococci | Brief Report

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

Authors: Helio S. Sader, Mariana Castanheira, Michael D. Huband, Dee Shortridge, Cecilia G. Carvalhaes, Rodrigo M. Mendes

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2022

Abstract

Dalbavancin and comparators were susceptibility tested against 8643 Gram-positive bacteria from 74 hospitals located in Europe and the United States by broth microdilution method. The most common organisms were Staphylococcus aureus (45.2%), Enterococcus faecalis (12.2%), and Staphylococcus epidermidis (8.9%), but rank order varied markedly by geographic region. Dalbavancin demonstrated potent activity and broad spectrum, with MIC₉₀ values of 0.03 mg/L for Staphylococcus aureus, β-haemolytic streptococci, and viridans group streptococci; 0.06 mg/L for Enterococcus faecalis and Staphylococcus epidermidis; and 0.12 mg/L for vancomycin-susceptible Enterococcus faecium. All organisms, except vancomycin-resistant enterococci and 1 Staphylococcus haemolyticus isolate, were inhibited at ≤ 0.25 mg/L of dalbavancin.

Kern WV, Rieg S (2020) Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect 26(2):151–157CrossRef

Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN (2019) The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 63(7):e00355CrossRef

McNamara JF, Righi E, Wright H, Hartel GF, Harris PNA, Paterson DL (2018) Long-term morbidity and mortality following bloodstream infection: a systematic literature review. J Infect 77(1):1–8CrossRef

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS (2018) Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16. J Antimicrob Chemother 73(10):2748–2756CrossRef

Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370(23):2169–2179CrossRef

Dalvance®, (2018) Package insert. Allergan USA Inc, Madison

Smith JR, Roberts KD, Rybak MJ (2015) Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 4(3):245–258CrossRef

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK (2018) Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. Antimicrob Agents Chemother 62(3):e02397CrossRef

Gatti M, Andreoni M, Pea F, Viale P (2021) Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Dev Ther 15:3349–3378CrossRef

10.

CLSI (2018) M07ED11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition. Clinical and Laboratory Standards Institute, Wayne

11.

CLSI (2021) M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Clinical and Laboratory Standards Institute, Wayne

12.

EUCAST (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing

13.

Nunez-Nunez M, PharmD M, Casas-Hidalgo I, Garcia-Fumero R, Vallejo-Rodriguez I, Anguita-Santos F, Hernandez-Quero J, Cabeza-Barrera J, Ruiz-Sancho A (2020) Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm 27(5):310–312CrossRef

14.

Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen MG, Winkler S, Thalhammer F (2018) Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 67(5):795–798CrossRef

15.

Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW (2022) Outcomes in patients with Staphylococcus aureus bacteremia treated with dalbavancin in clinical trials. Infect Dis Ther 11(1):423–434CrossRef

16.

Ajaka L, Heil E, Schmalzle S (2020) Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 9(10):700CrossRef

17.

Cho JC, Estrada SJ, Beltran AJ, Revuelta MP (2015) Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther 40(5):604–606CrossRef

18.

Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Davila P, Iftimie S, Sequera S, Loeches B, Lopez-Cortes LE, Farinas MC, Fernandez-Roldan C, Javier-Martinez R, Munoz P, Arenas-Miras MDM, Martinez-Marcos FJ, Miro JM, Herrero C, Bereciartua E, De Jesus SE, Pasquau J (2019) DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob 18(1):30CrossRef

19.

Hitzenbichler F, Mohr A, Camboni D, Simon M, Salzberger B, Hanses F (2021) Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection 49(1):181–186CrossRef

20.

Jones BM, Keedy C, Wynn M (2018) Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis 76:4–5CrossRef

21.

McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW (2015) In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. Antimicrob Agents Chemother 59(8):5007–5009CrossRef

22.

Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70(7):859–886CrossRef

Title: Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)
Authors: Helio S. Sader
Mariana Castanheira
Michael D. Huband
Dee Shortridge
Cecilia G. Carvalhaes
Rodrigo M. Mendes
Publication date: 01-05-2022
Publisher: Springer Berlin Heidelberg
Keywords: Streptococci
Linezolid
Vancomycin
Teicoplanin
Daptomycin
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2022
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-022-04437-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis

Risk factors for antibiotic resistance and mortality in patients with bloodstream infection of Escherichia coli

A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections

Non-structural protein 1 (NS1) variants from dengue virus clinical samples revealed mutations that influence NS1 production and secretion

The interplay between anticancer challenges and the microbial communities from the gut

Evaluation of the VITEK2 AST-XN17 card for the detection of carbapenemase-producing Enterobacterales in isolates primarily producing metallo β-lactamase

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page